Nebilet (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractile force. It also stimulates nitric‑oxide release from the endothelium, causing vasodilation. The combined effect reduces systemic vascular resistance and lowers blood pressure.

The appropriate dose of Nebilet is determined by the prescribing healthcare professional based on the individual’s clinical condition, response, and tolerability. Dosage adjustments may be required for specific patient groups, and the prescriber will provide the exact regimen.

Nebivolol’s safety in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Nebilet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nebilet (nebivolol) is a third‑generation β1‑selective blocker that also enhances nitric‑oxide‑mediated vasodilation, offering a more favourable metabolic profile and fewer central nervous system side effects compared with older non‑selective beta‑blockers such as propranolol.

Nebilet tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use after the expiry date.

Nebilet is taken orally as a tablet, usually with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks include severe bradycardia, marked hypotension, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as angioedema. Patients experiencing these symptoms should seek immediate medical attention.

Nebilet is contraindicated in patients with known hypersensitivity to nebivolol, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and individuals with uncompensated heart failure or severe hepatic impairment.